Best of heart failure

22 clear reasons, and they are stem. Recently, the advent inhibitor (ARNI) sacubi- rmacologic approach that al endopeptidase enzyme concomitantly blocks the ith valsartan). of ARNI with ACEI to rtality and Morbidity in tudy [ 31 ], a double-blind, patients with Class II–IV tion of 40% or less were itril/valsartan (at a dose of ectively) or enalapril (at a rimary outcome of death rt failure rehospitalization ARNI arm (21.8%) com- 01). Cardiovascular death % CI, 0.71; 0.89)) and risk n by 21% (HR 0.79 (95% lity was reduced by 16% HR 0.84 (95% CI, 0.76; y stopped because of the en compared to ACEI. ere reported in more than study, and these included gh, dizziness, and renal dema was also higher in pared to enalapril (0.5% in the black population). be encountered more fre- double-blind period of by a single-blind run-in ed if they could not toler- I. en tested in CHF patients . These include endothelin agents, and growth hor- terventions that modulate he neprilysin enzyme (in only proven treatment to patients with congestive t in treating patients with bradine, an HCN channel n normal sinus rhythm and or on maximum tolerable was tested in The Systolic inhibitor ivabradine Trial 505 patients with chronic bradine versus placebo on t. Patients had to be in rt rate of more or equal ss or equal 35%, and have N. W. Shammas 462 American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46:e1–e82. 50. Mandinov L, Eberli FR, Seiler C, Hess OM. Diastolic heart fail- ure. Cardiovasc Res. 2000;45:813–25. 51. Chang NC, Shih CM, BiWF, Lai ZY, LinMS,Wang TC. Fosinopril improves left ventricular diastolic function in young mildly hyper- tensive patients without hypertrophy. Cardiovasc Drugs Ther. 2002;16:141–7. 52. Yip GWK, Wang M, Wang T, Chan S, Fung JWH, Yeung L, Yip T, Lau ST, Lau CP, Tang MO, Yu CM, Sanderson JE. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capac- ity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008;94(5):573–80. 53. Roongsritong C, Sutthiwan P, Bradley J, Simoni J, Power S, Meyerrose GE. Spironolactone improves diastolic function in the elderly. Clin Cardiol. 2005;28:484–7. 54. The J-ELAN Investigators. Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to- moderate hypertension (J-ELAN). Circ J. 2006;70:124–8. 55. Yamamoto K, Ozaki H, Takayasu K, Akehi N, Fukui S, Sakai A, Kodama M, Shimonagata T, Kobayashi K, Ota M, Horiguchi Y, Ebisuno S, Katsube Y, Yamazaki T, Ohtsu H, Hori M. The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild- to-moderate hypertension (J-ELAN) study. Hypertens Res. 2011;34:325–30. 56. Bajraktari G, Koltai MS, Ademaj F, et al. Relationship between insulin r sistance and left ventricular diastolic dysfunction in patients with impaired glucose tolerance and type 2 diabetes. Int J Cardiol. 2006;110:206–11. 57. Charvat J, Michalova K, Chlumsky J, Valenta Z, Kvapil M. The association between left ventricle diastolic dysfunction and endo- the i l dysfunction and the results of stress myocardial SPECT in asymptomatic patients with type 2 diabetes. J Int Med Res. 2005;33:473–82. 58. Grandi AM, Piantanida E, Franzetti I, et al. Effect of glycemic control on left ventricular diastolic function in type 1 diabetes melli us. Am J Cardiol. 2006;97:71–6. 59. Komajda M, Hanon O, Hochadel M, Follath F, Swedberg K, Gitt A, Cleland JG. Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I. Eur Heart J. 2007;28:1310–8. 60. Rodeheffer RJ. The new epidemiology of heart failure. Curr Cardiol Rep. 2003;5:181–6. 61. Wang TJ, Evans JC, Benjamin EJ, et al. Natural history of left ventricular systolic dysfunction in the community. Circulation. 2003;108:977–82. 62. Franci GS, Benedict C, Johnstone DE, et al. Comparison of neu- roendocrine activation in patients with left ventricular dysfunc- tion with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724–9. 63. Das SR, Drazner MH, Yancy CW, Stevenson LW, Gersh BJ, Dries DL. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunc- tion to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention rial. Am Heart J. 2004;148:883–8. 64. Das SR, Dries DL, Drazner MH, Yancy CW, Chae CU. Relation of lower hematocrit to progression from asymptomatic left ven- tricular dysfunction to symptomatic heart failure (from the Studies of Left Ventricular Dysfunction Prevention trial). Am J Cardiol. 2005;96:827–31. 65. Dries DL, Strong MH, Cooper RS, Drazner MH. Efficacy of angiotensin-converting enzyme inhibition in reducing progres- sion from asymptomatic left ventricular dysfunction to symptom- atic heart failure in black and white patients. J Am Coll Cardiol. 2002;40:311–7. 66. Konstam MA, Kronenberg MW, Rousseau MF, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation. 1993;88(5 Pt 1):2277–83. 67. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007–18. 68. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med. 1992;327:685–91. 69. Eisenberg MJ, Gioia LC. Angiotensin II receptor blockers in con- gestive heart failure. Cardiol Rev. 2006;14:26–34. 70. Prasad SK, Dargie HJ, Smith GC, et al. Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascu- lar magnetic resonance study. Heart. 2006;92:798–803. 71. Zareba W, Piotrowicz K, McNitt S, Moss AJ, MADIT II Investigators. Implantable cardioverter–defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population). Am J Cardiol. 2005;95:1487–91. 72. Moss AJ. MADIT-I and MADIT-II. J Cardiovasc Electrophysiol. 2003;14(9 Suppl):S96–8. 73. Moss AJ, Zareba W, Hall WJ, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients withmyocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83. 74. ACC/AHA 2005 Guideline Update. Diagnosis and man- agement of chronic heart failure in the adult. Circulation. 2005;112:e154–235. 75. CONSENSUS Trial Study Group. Effects of enalapril on mortal- ity in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–35. 76. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302. 77. Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long- term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocar- diography substudy. Circulation. 1995;91:2573–81. 78. Pitt B. Use of converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction. J Am Coll Cardiol. 1993;22(4 Suppl A):158A–61A. 79. AIRE Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342:821–8. 80. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunc- tion after myocardial infarction. Results of the survival and ven- tricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669–77. 81. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333:1670–6. 82. Ambrosioni E, Borghi C, Magnani B. The effect of the angio- tensin–converting–enzyme inhibitor zofenopril on mortality and N. W. Shammas